Skip to content

Airway Disease Analysis and Prevention

Airway Disease Analysis and Prevention - ADAPT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00023381
Enrollment
800
Registered
2020-10-27
Start date
2019-05-28
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Asthma Chronic rhinosinusitis J30 J45 J32

Interventions

Group 1: Informed Consent Procedure Pregnancy test in urine for female patients with childbearing potential Clinical Examination of the respiratory tract Collection of serum and plasma, nasal secretio

Sponsors

Klinikum rechts der Isar der Technischen Universität München
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Individuals in good health otherwise from respiratory disease 2. Patients suffering from at least two symptoms that suggest Respiratory Inflammatory Disease: - Recurrent Sneeze - Itchy Eyes - Anterior or posterior rhinorrhea - Blocked Nose - Cough - Wheeze or Asthma attacks - Seasonal variation of airway symptoms 3. Age between 18 and 75 years

Exclusion criteria

Exclusion criteria: 1. Inability to understand or to communicate with investigator or to understand the aim of the study 2. Any currently relevant medical history of addiction to alcohol, drugs or medical substances 3. Any currently relevant medical history of clinically significant internal disease that is not primarily affecting the airways and that is not controlled by medication 4. Concommitant medication: Intake of topical nasal steroids, systemic leukotriene antagonists or any antihistamines within the last 7 days before study visit or systemic glucocorticoids within the last 10 days or Specific Immunotherapy within the last 5 years 5. Pregnancy

Design outcomes

Primary

MeasureTime frame
To assess sensitivity and specificity of biomarkers in local airway secretions in comparison to serum expression.

Secondary

MeasureTime frame
To assess tolerability of sampling methods.

Countries

Germany, Poland

Contacts

Public ContactClaudia Jerin

Klinikum rechts der Isar der Technischen Universität München

claudia.jerin@tum.de+498941406969

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026